CDCataldo Doria

Cataldo Doria

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cataldo Doria has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • QS197. Experience With Complete Steroid Avoidance in Adult Liver Transplantation

    by C.B. Ramirez, C. Doria, A.M. Frank, V. Navarro, S. Herrine, S. Rossi, M. Chaballa, S. Vaccino, S.T. Armenti, I.R. Marino

  • Anti-IL2 induction in liver trasplantation with 93% rejection free and 97% patient and graft survival at 24 months

    by C. Ramirez, C. Doria, F. di Francesco, M. Iaria, Y. Kang, I.R. Marino

  • Thromboelastography used to assess coagulation during treatment with molecular adsorbent recirculating system

    by Cataldo Doria, Lucio Mandalà, Jan D Smith, Giuseppe Caruana, Victor L Scott, Salvatore Gruttadauria, Mario Magnone, Ignazio R Marino

    Abstract:  Coagulopathy is a life‐threatening complication of liver cirrhosis. We describe the effect of molecular adsorbent recirculating system (MARS), a cell‐free dialysis technique, on the blood coagulation of cirrhotic patients.From February 2002 to July 2002, nine patients – five males (55.5%) and four females (44.4%), age 47–70 yr (median 56) – underwent 12 courses (4–7 sessions each) of MARS. Patients were treated for the following indications: six (66.6%) acute‐on‐chronic hepatic failure, three (33.3%) intractable pruritus. Platelet count, prothrombin time (PT), international standardized ratio and thromboelastography were measured before and after each MARS session. Coagulation factors II, V, VII, VIII, IX, X, XI, XII, XIII, von Willebrand, lupus anticoagulant, protein C, protein S, antithrombin III, plasminogen, α2 antiplasmin, d‐dimer, fibrin monomers, complement, and C1 inactivator were measured before and at the end of each MARS treatment.We found a statistically significant difference (p < 0.05) in the platelet count, PT, all the thromboelastograph variables (reaction and constant time, α angle, and maximal amplitude), factor VIII, von Willebrand, and d‐dimer, when measured before and after MARS.Previous reports have shown amelioration of blood coagulation following MARS treatments. However, we document that MARS induces coagulopathy through a platelet‐mediated mechanism, whereby platelet may be mechanically destroyed during the passage of blood through the filters and lines. An alternative postulated mechanism is an immune‐mediated platelet disruption – coagulopathy.


    • 14 January 2004
      • Vol. 88  (4) , 184-7

    Acute portal vein thrombosis secondary to donor/recipient portal vein diameter mismatch after orthotopic liver transplantation: a case report.

    by Cataldo Doria, Ignazio R Marino

    The incidence of portal vein thrombosis in end-stage liver disease is estimated as varying between 5% and 21%, whereas in candidates undergoing liver transplantation, this is 3-13%. Portal vein thrombosis occurring after liver transplantation can be managed surgically by thrombectomy, retransplantation, splenorenal shunt, or Wall-stent placement, or nonsurgically by angioplasty, local high-dose infusion of thrombolytic agents, combination of portal thrombolysis, or embolization of a pre-existing spontaneous splenorenal shunt. We report a case of portal vein thrombosis after liver transplantation diagnosed on postoperative day 1 in a 57-year-old patient who received a liver from an 8-year-old donor. The patient was successfully treated surgically with portal vein thrombectomy and systemic anticoagulation. Portal vein thrombosis, in this case, was considered to be secondary to size discrepancy between the donor and the recipient portal veins. Routine use of daily Doppler ultrasound was the key factor in early diagnosis.


    • 1 December 2003
      • Vol. 58  (6) , 791-5

    [Laparoscopic surgery for endoscopically irretrievable colonic polyps].

    by A Lauro, R Cirocchi, C Hamel, A Alonzo Poza, C Doria, S Gruttadauria, G Giustozzi, S D Wexner

    The vast majority of benign colorectal neoplasms can be safely removed by colonoscopic polypectomy; while peduncolated polyps can be easily endoscopically excised, the removal of sessile polyps may be more difficult. Between January 1997 and December 1998, 12 patients underwent laparoscopic or laparoscopic-assisted colonic resection for treatment of endoscopically irretrievable colonic polyps; this group was compared to 12 patients who underwent a laparotomic approach for polyps in the same period of time and to 23 patients who previously underwent similar laparoscopic resections. There were no significant differences between laparoscopic and laparotomic groups. Laparoscopic or laparoscopic-assisted colonic resection for treatment of endoscopically irretrievable colonic polyps remains our preferred method of treating these lesions.


  • Noncardiogenic pulmonary edema induced by a molecular adsorbent recirculating system: case report

    by Cataldo Doria, Victor L. Scott, Ignazio R. Marino, Salvatore Gruttadauria, Roberto Miraglia, Claudio H. Vitale, Jan Smith, Lucio Mandalà

    Noncardiogenic pulmonary edema is a well-recognized manifestation of acute lung injury which has been related, among others, to blood or blood-product transfusion, intravenous contrast injection, air embolism, and drug ingestion. We describe two cases of noncardiogenic pulmonary edema after use of a molecular adsorbent recirculating system, a cell-free dialysis technique. Patients in this series presented at our institution to be evaluated for liver transplantation. Subsequently, they developed an indication for the molecular adsorbent recirculating system. Two patients of 30 (6.6%) treated with the molecular adsorbent recirculating system for acute-on-chronic liver failure and intractable pruritus had normal chest X-rays before treatment and developed severe pulmonary edema, in the absence of cardiogenic causes, following use of the molecular adsorbent recirculating system. For each patient we reviewed the history of blood or blood-product transfusion, echocardiograms if available, daily chest X-rays, and when available pre- and postmolecular adsorbent recirculating systemic blood pressure, central venous pressure, pulmonary arterial pressures, cardiac output, cardiac index, systemic vascular resistance index, and arterial blood gas. Our data suggest that the molecular adsorbent recirculating system may cause noncardiogenic pulmonary edema, possibly by an immune-mediated mechanism.


  • Changes in Serum Electrolytes during Treatment of Patients in Liver Failure with Molecular Adsorbent Recirculating System

    by C. Doria, H.R. Doyle, L. Mandalà, I.R. Marino, G. Caruana, S. Gruttadauria, A. Lauro, M. Magnone, C. Scotti Foglieni, V. Lamonaca, et al.

    Purpose: To study the effect of MARS on serum electrolytes during liver failure. Design: Twenty-three patients admitted to a quaternary health care facility from September 2000 to May 2002, 22 adults and 1 child, 11 males (48%) and 12 females (52%), age 15–70 (median 53), treated with MARS for: 12 acute-on-chronic liver failure (52%); 4 fulminant hepatic failure (17%); 3 intractable pruritus (13%); 2 primary-non-function (9%); 2 following major liver resection (9%). Procedures: Sodium, potassium, chloride, phosphorus, calcium, and magnesium were measured in the serum, ultrafiltrate and albumin circuit before and after MARS. Statistical methods: A comparison of electrolyte concentrations, before and after MARS, was performed using a paired t test. Main findings: Serum electrolyte concentrations before and after MARS, while statistically significant in some cases, were very small, and of no clinical relevance. Conclusion: MARS exchanges potassium, chloride, calcium, and magnesium by ultrafiltration; sodium by the albumin dialysis.


    • 1 June 2003
      • Vol. 1  (1) , 48-55

    Conversion from tacrolimus to cyclosporine--a based immunosuppression following liver transplantation.

    by Cataldo Doria, Ashok Kumar B Jain, Victor L Scott, Salvatore Gruttadauria, Ignazio R Marino, Howard R Doyle, John J Fung

    We examined the frequency, reasons and outcome after conversion from Tacrolimus to Cyclosporine A. From August 1989 to December 1992, 1000 consecutive liver transplantation patients were studied, which included 834 adults (age>18 yr.) and 166 children with mean follow-up of 77 months (range 56 to 96). A prospectively populated electronic database was queried to identify patients that underwent conversion, the clinical indication and outcomes. Thirty-seven out of 834 adult recipients (4.43%), mean age of 48.4+/-12.9 years, 19 male (51.35%) and 18 females (48.64%) required conversion from Tacrolimus to Cyclosporine A baseline immunosuppressive therapy. No pediatric patient required conversion. The mean time interval from liver transplantation to Cyclosporine A conversion was 443.45+/-441.44 days (range 22 to 1641). The clinical indications for conversion included: 20 neurological (54%), 6 gastrointestinal (16%), 5 hematological (14%), and 6 other (16%) scenarios. Seven of the 37 patients (18.9%) died. The causes of death were multi-organ failure (2), sepsis (2), pancreatitis (1), hepatic failure due to relapse of ethanol abuse (1), and unknown cause (1). Nine out of 37 patients (24.32%) had to be reconverted to Tacrolimus (mean 282.22+/-499.79 days; range 15 to 1583 day with a median of 135) after institution of Cyclosporine A; none showed recurrence of the original symptoms. The reasons for these re-conversions were acute cellular rejection (44%, n=4), chronic rejection (11%, n=1), increased hepatic enzymes (33%, n=3) and progressively worsening neurological symptoms (11%, n=1). The frequency of conversion from Tacrolimus to Cyclosporine A was 4.43%. Conversion is safe and efficacious if done in a controlled setting. Additionally, re-conversion to Tacrolimus for lack of efficacy of Cyclosporine A did not appear to be associated with a recurrence of the condition that caused the initial switch.